KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

Histone deacetylase (HDAC) inhibitors have garnered significant attention as cancer drugs. These therapeutic agents have recently been clinically validated with the market approval of vorinostat (SAHA, Zolinza) for treatment of cutaneous T-cell lymphoma. Like vorinostat, most of the small-molecule HDAC inhibitors in clinical development are hydroxamic acids, whose inhibitory activity stems from their ability to coordinate the catalytic Zn2+ in the active site of HDACs. We sought to identify novel, nonhydroxamate-based HDAC inhibitors with potentially distinct pharmaceutical properties via an ultra-high throughput small molecule biochemical screen against the HDAC activity in a HeLa cell nuclear extract. An α-mercaptoketone series was identified and chemically optimized. The lead compound, KD5170, exhibits HDAC inhibitory activity with an IC50 of 0.045 μmol/L in the screening biochemical assay and an EC50 of 0.025 μmol/L in HeLa cell–based assays that monitor histone H3 acetylation. KD5170 also exhibits broad spectrum classes I and II HDAC inhibition in assays using purified recombinant human isoforms. KD5170 shows significant antiproliferative activity against a variety of human tumor cell lines, including the NCI-60 panel. Significant tumor growth inhibition was observed after p.o. dosing in human HCT-116 (colorectal cancer), NCI-H460 (non–small cell lung carcinoma), and PC-3 (prostate cancer) s.c. xenografts in nude mice. In addition, a significant increase in antitumor activity and time to end-point occurred when KD5170 was combined with docetaxel in xenografts of the PC-3 prostate cancer cell line. The biological and pharmaceutical profile of KD5170 supports its continued preclinical and clinical development as a broad spectrum anticancer agent. [Mol Cancer Ther 2008;7(5):1054–65]

[1]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[2]  Y. Oda,et al.  Expression profile of class I histone deacetylases in human cancer tissues. , 2007, Oncology reports.

[3]  K. Glaser.  HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.

[4]  C. Allis,et al.  Chromatin remodeling and cancer, Part I: Covalent histone modifications. , 2007, Trends in molecular medicine.

[5]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[6]  John N Weinstein,et al.  MicroRNA expression profiles for the NCI-60 cancer cell panel , 2007, Molecular Cancer Therapeutics.

[7]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[8]  P. Marks,et al.  Discovery and development of SAHA as an anticancer agent , 2007, Oncogene.

[9]  A. El-Osta,et al.  Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? , 2007, Leukemia.

[10]  K. Anderson,et al.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.

[11]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[12]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[13]  A. El-Osta,et al.  Clinical Potential of Histone Deacetylase Inhibitors as Stand Alone Therapeutics and in Combination with other Chemotherapeutics or Radiotherapy for Cancer , 2006, Epigenetics.

[14]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[15]  M. Pino,et al.  Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. , 2006, Cancer research.

[16]  A. Sagalowsky,et al.  The application of epigenetic modifiers on the treatment of prostate and bladder cancer. , 2006, Urologic oncology.

[17]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[18]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[19]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[20]  P. Geerlings,et al.  DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry.

[21]  Takayoshi Suzuki,et al.  Non-hydroxamate histone deacetylase inhibitors. , 2005, Current medicinal chemistry.

[22]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[23]  P. Atadja,et al.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 , 2005, Molecular Cancer Therapeutics.

[24]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[25]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Marks,et al.  Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy , 2005, Cell cycle.

[28]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[29]  S. Baylin,et al.  Aberrant gene silencing in tumor progression: implications for control of cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[30]  A. Kohara,et al.  Thiol-based SAHA analogues as potent histone deacetylase inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[31]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[33]  S. Remiszewski.  The discovery of NVP-LAQ824: from concept to clinic. , 2003, Current medicinal chemistry.

[34]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[35]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[36]  G. Gores,et al.  Calpains Can Do It Alone: Implications for Cancer Therapy , 2003, Cancer biology & therapy.

[37]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.

[38]  R. Brachmann,et al.  Chromatin Remodeling and Cancer , 2003, Cancer biology & therapy.

[39]  S. Horinouchi,et al.  In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.

[40]  J. Marshall,et al.  A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. , 2002, Journal of experimental therapeutics & oncology.

[41]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[42]  J. Fargnoli,et al.  Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. , 2001, Cancer research.

[43]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[44]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[45]  Tony Kouzarides,et al.  Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.

[46]  L. Pustilnik,et al.  Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[47]  S. Schreiber,et al.  A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Sakai,et al.  Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. , 1997, Biochemical and biophysical research communications.

[49]  C. Franceschi,et al.  JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis , 1997, FEBS letters.

[50]  B. Rubin,et al.  Captopril (SQ 14,225) (D-3-mercapto-2-methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. , 1978, Progress in cardiovascular diseases.